Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
暂无分享,去创建一个
G. Filippatos | L. Ruilope | G. Bakris | S. Anker | B. Pitt | P. Rossing | R. Agarwal | P. Kolkhof | C. Nowack | Patrick Schloemer | A. Joseph
[1] I. Hirsch,et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.
[2] G. Bakris,et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.
[3] Jun Lyu,et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017 , 2020, Journal of diabetes investigation.
[4] E. Braunwald,et al. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[5] C. Mathieu,et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetologia.
[6] 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020 , 2019, Diabetes Care.
[7] G. Filippatos,et al. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial , 2019, American Journal of Nephrology.
[8] G. Filippatos,et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial , 2019, American Journal of Nephrology.
[9] F. Jaisser,et al. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. , 2019, Kidney international.
[10] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[11] F. Jaisser,et al. Mineralocorticoid Receptor and Cardiovascular Disease , 2018, American journal of hypertension.
[12] S. Lechner,et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. , 2018, Kidney international.
[13] R. Klopfleisch,et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity , 2018, Hypertension.
[14] S. Lechner,et al. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease: Role of Oxidative Stress , 2017, Hypertension.
[15] G. Filippatos,et al. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. , 2017, Handbook of experimental pharmacology.
[16] A. Jardine,et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis , 2016, BMC Nephrology.
[17] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[18] L. Ruilope,et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. , 2015, JAMA.
[19] F. Eitner,et al. Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury , 2014, Journal of cardiovascular pharmacology.
[20] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[21] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[22] J. Chan,et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study , 2011, Diabetologia.
[23] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[24] G. Adler,et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. , 2006, Endocrinology.